a lonely feeling
is all around this webpage
can't find one like it
If you are certain you have the correct web address but are encountering an error, please contact the Site Administration. Thank you.
You are seeing this haiku because the page you were looking for cannot be found.
We apologize for the inconvenience, but the page you were trying to access is not at this address. You can use the links below to help you find what you are looking for.
You might have been looking for…
-
PACMEL: A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma
PACMEL: A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma
- Phase II trial Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
-
A practical application of time to event analysis in the presence of non-proportional hazards
The proportional hazards (PH) model is commonly used to measure the between-group difference under the assumption that the ratio of the two hazard function is ...
-
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.
BACKGROUND: We sought to determine the maximal tolerated dose of the MEK inhibitor trametinib with weekly paclitaxel, with a view to exploring the ...
-
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.
Backround: Advanced melanoma treatments often rely on immunotherapy or targeting mutations, with few treatment options for wild-type BRAF (BRAF-wt) melanoma. ...